Bavarian Nordic (OTCMKTS:BVNRY) Announces Quarterly Earnings Results

Bavarian Nordic (OTCMKTS:BVNRY) announced its quarterly earnings results on Wednesday. The company reported $0.01 EPS for the quarter, Zacks reports. Bavarian Nordic had a net margin of 22.20% and a return on equity of 11.27%.

Bavarian Nordic Stock Down 4.7%

BVNRY stock traded down $0.48 during mid-day trading on Wednesday, hitting $9.82. The company had a trading volume of 3,013 shares, compared to its average volume of 3,490. The company has a market capitalization of $2.33 billion, a price-to-earnings ratio of 11.16 and a beta of 1.21. Bavarian Nordic has a 12-month low of $7.94 and a 12-month high of $13.00. The company has a 50-day moving average price of $9.86 and a 200 day moving average price of $10.10.

Bavarian Nordic Company Profile

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.